24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy
Dermatitis® · 2026
DOI: 10.1089/derm.2025.0045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Dermatitis®, 2026. Verfasst von Teppei Hagino und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
The data are limited on the real-world effectiveness of an anti-interleukin (IL)-13 monoclonal antibody lebrikizumab for atopic dermatitis (AD).
Objective
To evaluate the 24-week real-world effectiveness of lebrikizumab in Japanese patients with AD, stratified by the presence or absence of prior systemic therapy.
Methods
We conducted a multicenter, prospective study of 134 Japanese AD patients treated with lebrikizumab. We evaluated clinical outcomes throughout a 24-week period in patients with or without prior systemic therapy.
Results
Among lebrikizumab-treated patients, eczema area and severity index (EASI) and scores of patient-reported outcomes (peak pruritus numerical rating scale, sleep quality numerical rating scale, AD control tool, dermatology life quality index, and patient-oriented eczema measure) rapidly decreased until week 12, and these improvements persisted until week 24. At week 24, the achievement rates of EASI 75, EASI 90, and investigator’s global assessment 0/1 in systemic therapy-naïve patients were 75.6%, 58.5%, and 43.5%, respectively, which were higher than those in systemic therapy-experienced patients, 55.5%, 22.2%, and 26.9%, respectively. There were no serious treatment-emergent adverse events until week 24.
Conclusion
Lebrikizumab treatment provided favorable effectiveness and tolerability for AD in real-world practice, with slightly higher effectiveness in systemic therapy-naïve patients compared to therapy-experienced patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino
Zitieren
APA
Hagino, T., Uchiyama, A., Onda, M., Kosaka, K., Araki, T., Motegi, S. I., Saeki, H., Fujimoto, E., & Kanda, N. (2026). 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis®. https://doi.org/10.1089/derm.2025.0045
Vancouver
Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis®. 2026. doi:10.1089/derm.2025.0045
BibTeX
@article{Hagino2026,
author = {Hagino, Teppei and Uchiyama, Akihiko and Onda, Marina and Kosaka, Keiji and Araki, Takeshi and Motegi, Sei-Ichiro and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy},
journal = {Dermatitis®},
year = {2026},
doi = {10.1089/derm.2025.0045}
}
EUVIMED